Evidence map›Paper›PMID 28973954›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2017

Extracellular vesicles from human pancreatic islets suppress human islet amyloid polypeptide amyloid formation.

Diana Ribeiro, Istvan Horvath, Nikki Heath, Ryan Hicks, Anna Forslöw, Pernilla Wittung-Stafshede

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 41 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Diana RibeiroDiscovery Biology, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, 43150 Mölndal, Sweden.
Istvan HorvathDepartment of Biology and Biological Engineering, Chalmers University of Technology, 41258 Gothenburg, Sweden.
Nikki HeathDiscovery Biology, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Alderley Park SK10 4TG, United Kingdom.
Ryan HicksDiscovery Biology, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, 43150 Mölndal, Sweden.
Anna ForslöwDiscovery Biology, Innovative Medicines and Early Development Biotech Unit, AstraZeneca, 43150 Mölndal, Sweden.
Pernilla Wittung-StafshedeDepartment of Biology and Biological Engineering, Chalmers University of Technology, 41258 Gothenburg, Sweden; pernilla.wittung@chalmers.se.ORCID 0000-0003-1058-1964
AstraZeneca (Sweden) · SEChalmers University of Technology · SEAstraZeneca (United Kingdom) · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extracellular vesicles (EVs) are small vesicles released by cells to aid cell-cell communication and tissue homeostasis. Human islet amyloid polypeptide (IAPP) is the major component of amyloid deposits found in pancreatic islets of patients with type 2 diabetes (T2D). IAPP is secreted in conjunction with insulin from pancreatic β cells to regulate glucose metabolism. Here, using a combination of analytical and biophysical methods in vitro, we tested whether EVs isolated from pancreatic islets of healthy patients and patients with T2D modulate IAPP amyloid formation. We discovered that pancreatic EVs from healthy patients reduce IAPP amyloid formation by peptide scavenging, but T2D pancreatic and human serum EVs have no effect. In accordance with these differential effects, the insulin:C-peptide ratio and lipid composition differ between EVs from healthy pancreas and EVs from T2D pancreas and serum. It appears that healthy pancreatic EVs limit IAPP amyloid formation via direct binding as a tissue-specific control mechanism.

Indexed as

AdultAgedCase-Control StudiesDiabetes Mellitus, Type 2Extracellular VesiclesFemaleHumansIslet Amyloid PolypeptideIslets of LangerhansMaleMiddle AgedPlaque, AmyloidYoung AdultIslet Amyloid Polypeptideamyloidatomic force microscopyelectron microscopyextracellular vesiclestype 2 diabetes

Identifiers

PMID28973954
PMCPMC5651775
OpenAlexW2762662190

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.